Climb Bio (CLYM) Registration Filing summary

Company overview and business model

• Clinical-stage biotechnology company focused on developing therapeutics for immune-mediated diseases.

• Lead product candidate is budoprutug, an anti-CD19 monoclonal antibody targeting B-cell mediated diseases such as PMN, ITP, and SLE.

• Budoprutug is designed for broad B-cell depletion with a favorable tolerability profile and potential for subcutaneous administration.

• Recent Phase 1b trial in PMN showed 60% complete remission of proteinuria and sustained B-cell depletion in all patients.

• Company recently changed its name from Eliem Therapeutics, Inc. to Climb Bio, Inc.

Use of proceeds and capital allocation

• Net proceeds from any securities sale will be used for general corporate purposes, including R&D, manufacturing, commercialization, acquisitions, working capital, and capital expenditures.

• Management retains broad discretion over allocation of net proceeds.

Risk factors and disclosures

• Investment involves a high degree of risk, with risks detailed in the prospectus supplement, annual and quarterly reports, and other SEC filings.

• Risks could adversely affect business, operations, financial condition, and investment value.